[
  {
    "ts": null,
    "headline": "Johnson & Johnson (NYSE:JNJ) Reports Positive Phase 2b Trial Results For Ulcerative Colitis Treatment",
    "summary": "Johnson & Johnson (NYSE:JNJ) recently experienced a 12% price increase over the last quarter, largely driven by significant announcements regarding its clinical trials, particularly the ANTHEM-UC study, which showcased promising results in ulcerative colitis treatment. These positive results provided a boost to investor confidence amid overall market volatility, triggered by economic concerns and trade issues, including tariffs announced by the Trump administration. The broader market faced a...",
    "url": "https://finnhub.io/api/news?id=dbfce4c852824063f9db499eb83b0e2d015f5525e6bf3b6bd7439bb5f77f24c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741714590,
      "headline": "Johnson & Johnson (NYSE:JNJ) Reports Positive Phase 2b Trial Results For Ulcerative Colitis Treatment",
      "id": 133184442,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) recently experienced a 12% price increase over the last quarter, largely driven by significant announcements regarding its clinical trials, particularly the ANTHEM-UC study, which showcased promising results in ulcerative colitis treatment. These positive results provided a boost to investor confidence amid overall market volatility, triggered by economic concerns and trade issues, including tariffs announced by the Trump administration. The broader market faced a...",
      "url": "https://finnhub.io/api/news?id=dbfce4c852824063f9db499eb83b0e2d015f5525e6bf3b6bd7439bb5f77f24c3"
    }
  },
  {
    "ts": null,
    "headline": "Legend Biotech's Carvykti Is Taking Off, And It's Still Early (Rating Upgrade)",
    "summary": "Carvykti's success boosts Legend Biotech Corporation's Q4 2024 sales to $334M, solidifying market position. Click for my updated look at LEGN earnings.",
    "url": "https://finnhub.io/api/news?id=9f1910c5e487ba2c0ff679899a263343373f86252cee9e7c7170cdfe7c22f59d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741710774,
      "headline": "Legend Biotech's Carvykti Is Taking Off, And It's Still Early (Rating Upgrade)",
      "id": 133139425,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2189063052/image_2189063052.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Carvykti's success boosts Legend Biotech Corporation's Q4 2024 sales to $334M, solidifying market position. Click for my updated look at LEGN earnings.",
      "url": "https://finnhub.io/api/news?id=9f1910c5e487ba2c0ff679899a263343373f86252cee9e7c7170cdfe7c22f59d"
    }
  },
  {
    "ts": null,
    "headline": "PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study",
    "summary": "The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.",
    "url": "https://finnhub.io/api/news?id=51d6b6a1088bc2bbd46313bd614410d7fa56bacd4c5f21889dfcea00d570df1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741709700,
      "headline": "PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study",
      "id": 133184443,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.",
      "url": "https://finnhub.io/api/news?id=51d6b6a1088bc2bbd46313bd614410d7fa56bacd4c5f21889dfcea00d570df1a"
    }
  },
  {
    "ts": null,
    "headline": "Is Johnson & Johnson (JNJ) the Best Low Risk Stock to Buy In 2025?",
    "summary": "We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other low risk stocks. Risk is a key consideration in investing and portfolio management, as investors generally aim to achieve the […]",
    "url": "https://finnhub.io/api/news?id=8022d6dfccade734b4ea6607990bf0cf80a76ace195eeadc7dc256e0a6737b58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741709274,
      "headline": "Is Johnson & Johnson (JNJ) the Best Low Risk Stock to Buy In 2025?",
      "id": 133184444,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other low risk stocks. Risk is a key consideration in investing and portfolio management, as investors generally aim to achieve the […]",
      "url": "https://finnhub.io/api/news?id=8022d6dfccade734b4ea6607990bf0cf80a76ace195eeadc7dc256e0a6737b58"
    }
  },
  {
    "ts": null,
    "headline": "Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It",
    "summary": "Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis. Click fo rmy PTGX update.",
    "url": "https://finnhub.io/api/news?id=9e0337c08ddb883be885c55f1206f206b8fb08bfd2f83fd9ca8c00378b311f90",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741708809,
      "headline": "Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It",
      "id": 133139254,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222145/image_2194222145.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis. Click fo rmy PTGX update.",
      "url": "https://finnhub.io/api/news?id=9e0337c08ddb883be885c55f1206f206b8fb08bfd2f83fd9ca8c00378b311f90"
    }
  },
  {
    "ts": null,
    "headline": "Genmab says J&J not exercising option on HexaBody-CD38",
    "summary": "Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38. “While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio prioritization, Genmab will not pursue further clinical development of HexaBody-CD38,” the company said in a state",
    "url": "https://finnhub.io/api/news?id=270b4c5128d4f774c864e4436dc2ea69e13e910ae7874d5f40069ee86f0eaf64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741702818,
      "headline": "Genmab says J&J not exercising option on HexaBody-CD38",
      "id": 133184445,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38. “While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio prioritization, Genmab will not pursue further clinical development of HexaBody-CD38,” the company said in a state",
      "url": "https://finnhub.io/api/news?id=270b4c5128d4f774c864e4436dc2ea69e13e910ae7874d5f40069ee86f0eaf64"
    }
  },
  {
    "ts": null,
    "headline": "Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success",
    "summary": "PTGX Achieves First Profit in 2024 Amid Clinical Milestones and Financial Turnaround",
    "url": "https://finnhub.io/api/news?id=fc490eb1abff01cd40056e7fead78259d3f663dc6fc4aebd836e1491f1226544",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741699755,
      "headline": "Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success",
      "id": 133184446,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "PTGX Achieves First Profit in 2024 Amid Clinical Milestones and Financial Turnaround",
      "url": "https://finnhub.io/api/news?id=fc490eb1abff01cd40056e7fead78259d3f663dc6fc4aebd836e1491f1226544"
    }
  },
  {
    "ts": null,
    "headline": "BMEZ: Recession Fears Making You Sick? Buy This High-Yield Healthcare Fund",
    "summary": "BlackRock Health Sciences Term Trust is a top pick for high-yield dividends in healthcare. Click here to find out why BMEZ stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=0a90bbc72c21544b52437a24252fdcd27158f61d0b5128e17ea6b2ed0058f641",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741698125,
      "headline": "BMEZ: Recession Fears Making You Sick? Buy This High-Yield Healthcare Fund",
      "id": 133136036,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148098716/image_2148098716.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "BlackRock Health Sciences Term Trust is a top pick for high-yield dividends in healthcare. Click here to find out why BMEZ stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=0a90bbc72c21544b52437a24252fdcd27158f61d0b5128e17ea6b2ed0058f641"
    }
  },
  {
    "ts": null,
    "headline": "J&J and Protagonist’s icotrokinra scores in Phase IIb UC study",
    "summary": "GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of $2.19bn in 2030.",
    "url": "https://finnhub.io/api/news?id=62388b95a0dcdff8b30fe25db608654bf7cbcc4eecdd13dd8af0f30d3a7250a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741696667,
      "headline": "J&J and Protagonist’s icotrokinra scores in Phase IIb UC study",
      "id": 133184447,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of $2.19bn in 2030.",
      "url": "https://finnhub.io/api/news?id=62388b95a0dcdff8b30fe25db608654bf7cbcc4eecdd13dd8af0f30d3a7250a0"
    }
  },
  {
    "ts": null,
    "headline": "Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded",
    "summary": "Investing.com -- Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their megablockbuster cancer drug, Darzalex.",
    "url": "https://finnhub.io/api/news?id=f421e08d5d9cb09b19152c1cd2d57e7ee30352a2b65098fcf5082991c79574d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741691214,
      "headline": "Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded",
      "id": 133184448,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Investing.com -- Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their megablockbuster cancer drug, Darzalex.",
      "url": "https://finnhub.io/api/news?id=f421e08d5d9cb09b19152c1cd2d57e7ee30352a2b65098fcf5082991c79574d7"
    }
  },
  {
    "ts": null,
    "headline": "Investigational plaque psoriasis treatments show promise in late-stage trials",
    "summary": "Newly released Phase III data illustrate potential of three drugs being investigated as treatments for plaque psoriasis—namely two monoclonal antibodies and an oral peptide, from pharmaceutical...",
    "url": "https://finnhub.io/api/news?id=eb4aef1c7ee8f58d6802d4c0686ddfc0ddcf6762fd2bfa33b3c0da587bf0515d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741683739,
      "headline": "Investigational plaque psoriasis treatments show promise in late-stage trials",
      "id": 133132105,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Newly released Phase III data illustrate potential of three drugs being investigated as treatments for plaque psoriasis—namely two monoclonal antibodies and an oral peptide, from pharmaceutical...",
      "url": "https://finnhub.io/api/news?id=eb4aef1c7ee8f58d6802d4c0686ddfc0ddcf6762fd2bfa33b3c0da587bf0515d"
    }
  }
]